This article is more than 5 years old. Information may no longer be current.

Latanoprost lowered diurnal IOP in normal-tension glaucoma patients, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Latanoprost significantly reduced IOP throughout the day and night in patients with normal-tension glaucoma without their affecting blood pressure or ocular perfusion pressure, a study found.

Toshiaki Kubota, MD, PhD, of the University of Occupational and Environmental Health in Kitakyushu, Japan, and colleagues evaluated the efficacy of Xalatan (latanoprost 0.005%, Pfizer) in controlling diurnal variations in IOP in 22 eyes of 22 patients with normal-tension glaucoma.

After 3 months of daily treatment, latanoprost produced a significant (P < .001) decrease in IOP at all time points measured over 24 hours but did not significantly affect blood pressure or ocular perfusion pressure compared to baselines levels, according to the study.

The study is published in the October issue of the Journal of Glaucoma.